EU pharma sector inquiry -- the IPI response

The Intellectual Property Institute has prepared a paper for the EU Commission in response to the DG Competition Inquiry into the pharmaceutical sector (on which see IPKat posts here and here). Since responses have not yet apparently been posted on the Commission website, the IPKat is taking the liberty of pinning the IPI's response here. This response reflects the efforts of Duncan Curley and Steve Smith, who had to work to a very tight time framework and who, all things considered, have done a pretty good job.

Right: the IPKat has his own opinion about pharmaceutical products, but for once he's keeping his mouth shut.

STOP PRESS: the IPKat has just received the response of the Intellectual Property Lawyers' Association (IPLA) to the same Inquiry.  You can read the IPLA response here.
EU pharma sector inquiry -- the IPI response EU pharma sector inquiry -- the IPI response Reviewed by Jeremy on Thursday, February 05, 2009 Rating: 5


  1. and CIPA's response is here:


All comments must be moderated by a member of the IPKat team before they appear on the blog. Comments will not be allowed if the contravene the IPKat policy that readers' comments should not be obscene or defamatory; they should not consist of ad hominem attacks on members of the blog team or other comment-posters and they should make a constructive contribution to the discussion of the post on which they purport to comment.

It is also the IPKat policy that comments should not be made completely anonymously, and users should use a consistent name or pseudonym (which should not itself be defamatory or obscene, or that of another real person), either in the "identity" field, or at the beginning of the comment. Current practice is to, however, allow a limited number of comments that contravene this policy, provided that the comment has a high degree of relevance and the comment chain does not become too difficult to follow.

Learn more here:

Powered by Blogger.